These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 32760020)
21. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Trivedi K; Le V; Nelson JR Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268 [TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective. Gao L; Moodie M; Li SC Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124 [TBL] [Abstract][Full Text] [Related]
23. Risk of Total Events With Icosapent Ethyl: Can We Reduce It? Granger CB; Nelson AJ; Pagidipati NJ J Am Coll Cardiol; 2019 Jun; 73(22):2803-2805. PubMed ID: 31171085 [No Abstract] [Full Text] [Related]
24. Federal court invalidates Sanofi's Plavix patent for alleged insufficiency and obviousness. Folkins P Health Law Can; 2012 Feb; 32(3):46-8. PubMed ID: 22458154 [No Abstract] [Full Text] [Related]
25. The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction. Wang X; Verma S; Mason RP; Bhatt DL Curr Diab Rep; 2020 Oct; 20(11):65. PubMed ID: 33095318 [TBL] [Abstract][Full Text] [Related]
26. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351 [TBL] [Abstract][Full Text] [Related]
27. Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Jiao L; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM; J Am Coll Cardiol; 2019 Aug; 74(8):1159-1161. PubMed ID: 31439224 [No Abstract] [Full Text] [Related]
28. Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke. Myran L; Nguyen TN Am Fam Physician; 2021 Jan; 103(2):117-118. PubMed ID: 33448769 [No Abstract] [Full Text] [Related]
29. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Jia X; Akeroyd JM; Nasir K; Nambi V; Ballantyne CM; Petersen LA; Virani SS Circulation; 2019 Mar; 139(10):1341-1343. PubMed ID: 30865483 [No Abstract] [Full Text] [Related]
31. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Orringer CE; Jacobson TA; Maki KC J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586 [TBL] [Abstract][Full Text] [Related]